Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9504 Authors: Reinhard Dummer, Paolo Antonio Ascierto,...
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Patient and Survivor Care Abstract number: 10 038 Authors: Francesco De Rosa,...
Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9552 Authors: Allison Betof Warner, Alexander Noor...
Four-Year Data Show Durable Effect of Pembrolizumab in Advanced Melanoma
23 septembra, 2020 4:52 pmJune 4, 2018 The anti–PD-1 antibody pembrolizumab previously demonstrated superior overall survival (OS) in patients with advanced melanoma compared...
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9505 Authors: Suzanne Louise Topalian, Shailender Bhatia,...
Neoadjuvant Nivolumab Leads to Tumor Regression in Resectable Merkel Cell Carcinoma
23 septembra, 2020 4:52 pmJune 4, 2018 The PD-1/PD-L1 pathway is commonly upregulated in Merkel cell carcinoma (MCC), a rare aggressive form of skin...
Léčba metastazujícího melanomu na ASCO 2018
23 septembra, 2020 4:52 pmImunoterapie i cílená léčba dokázaly významně zlepšit prognózu nemocných s metastazujícím melanomem, přesto zůstává ještě téměř polovina nemocných bez léčebné odpovědi či...
Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial
23 septembra, 2020 4:52 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5001 Authors: Wolfgang Fendler, Jeremie Calais,...
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4504 Authors: Jonathan E. Rosenberg, Srikala...
First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
23 septembra, 2020 4:51 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4503 Authors: Arlene O. Siefker-Radtke, Andrea...